BEIHAI GOFAR CHUANSHAN BIOLOGICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.8 CNY | -1.44% |
|
+3.23% | +3.45% |
| Sales 2022 | 460M 63.44M | Sales 2023 | 369M 50.95M | Capitalization | 2.43B 336M |
|---|---|---|---|---|---|
| Net income 2022 | 34M 4.69M | Net income 2023 | -82M -11.32M | EV / Sales 2022 | 4.81 x |
| Net cash position 2022 | 156M 21.58M | Net cash position 2023 | 139M 19.25M | EV / Sales 2023 | 6.21 x |
| P/E ratio 2022 |
64.6
x | P/E ratio 2023 |
-29
x | Employees | 501 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 66.14% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.44% | ||
| 1 week | +3.23% | ||
| Current month | +0.63% | ||
| 1 month | -0.62% | ||
| 3 months | +9.09% | ||
| 6 months | +11.37% | ||
| Current year | +3.45% |
1 week
4.67
4.99
1 month
4.315.34
Current year
3.205.34
1 year
3.205.34
3 years
3.2010.76
5 years
3.2010.76
10 years
3.0619.58
| Managers | Title | Age | Since |
|---|---|---|---|
Li Bin Pan
CEO | Chief Executive Officer | 60 | 09-09-24 |
Zhi Bo Yin
DFI | Director of Finance/CFO | 57 | 10-05-17 |
Yong Li
BRD | Director/Board Member | 59 | 00-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Li Bin Pan
CEO | Chief Executive Officer | 60 | 09-09-24 |
Yong Li
BRD | Director/Board Member | 59 | 00-12-31 |
Yan Chen
BRD | Director/Board Member | 41 | 11-04-06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 4.8 | -1.44% | 9,943,700 |
| 24-04-24 | 4.87 | +0.62% | 12,329,080 |
| 24-04-23 | 4.84 | +0.21% | 5,442,982 |
| 24-04-22 | 4.83 | -2.23% | 7,044,800 |
| 24-04-19 | 4.94 | +6.24% | 11,497,200 |
End-of-day quote Shanghai S.E., April 24, 2024
More quotes
Beihai Gofar Chuanshan Biological Co Ltd, formerly Beihai Gofar Marine Biological Industry Co Ltd, is a China-based company mainly engaged in the production and sales of pharmaceutical products and pesticide products. The Company is mainly engaged in the Pharmaceutical Distribution segment, the Pharmaceutical Manufacturing segment, the Deoxyribonucleic Acid Identification and Service segment, and the Other segment. The Company is mainly engaged in pharmaceutical manufacturing and pharmaceutical distribution industries, molecular medical imaging centers, tumor radiotherapy centers, and tumor telemedicine technical services, molecular diagnostics and judicial identification technical services. The Company mainly sells its products in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +3.45% | 347M | |
| +16.62% | 70.95B | |
| +2.99% | 25.25B | |
| +5.38% | 8.67B | |
| +6.46% | 8.16B | |
| -21.01% | 7.91B | |
| -0.12% | 4.51B | |
| +17.12% | 4.31B | |
| -0.14% | 4.07B | |
| -3.57% | 3.84B |
- Stock Market
- Equities
- 600538 Stock
